Pricing & Access· May 27, 2026 · 12 min readYescarta vs Tecartus CAR-T access guide: CD19-directed axi-cel vs brexu-cel payer coverage, REMS elimination, center certification, billing, and one-time authorizationYescarta (axicabtagene ciloleucel) and Tecartus (brexucabtagene autoleucel) are Kite/Gilead CD19-directed CAR T-cell therapies for...By Ran Chen#Oncology#CAR-T#Prior Authorization
